Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database
| Autor: | Nicholas W. Sterling, Guodong Liu, Douglas L. Leslie, Honglei Chen, Xuemei Huang, Lan Kong, Richard B. Mailman, Mechelle M. Lewis |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Statin Parkinson's disease medicine.drug_class Cross-sectional study business.industry Case-control study Retrospective cohort study Odds ratio medicine.disease Antiparkinson medication 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Neurology Internal medicine medicine Neurology (clinical) Diagnosis code business 030217 neurology & neurosurgery |
| Zdroj: | Movement Disorders. 32:913-917 |
| ISSN: | 0885-3185 |
| DOI: | 10.1002/mds.27006 |
| Popis: | Objective Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). Methods We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD. Results Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P < .0001) versus hydrophilic (odds ratio = 1.19, P = .25) statins, statins plus nonstatins (odds ratio = 1.95, P < .0001), and for the initial period after starting statins ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text